» Articles » PMID: 38465636

Efficacy of the COVID-19 Vaccination in Patients with Asymptomatic or Mild Illness During the Omicron Epidemic in Guangzhou: a Multi-centre Retrospective Cohort Study

Overview
Journal Ann Med
Publisher Informa Healthcare
Specialty General Medicine
Date 2024 Mar 11
PMID 38465636
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the widespread administration of coronavirus disease 2019 (COVID-19) vaccines, the impact on patients with asymptomatic to mild illness remains unclear. Here, we aimed to assess the efficacy of various vaccine doses and types on the duration of isolation duration and discharge rates, the viral shedding duration, and negative rates in asymptomatic to mild COVID-19 patients.

Methods: We included adult patients at the Fangcang isolation centres in Pazhou or Yongning between November and December 2022. We analysed data on basic demographics, admission details, laboratory indicators and vaccination information.

Results: A total of 6560 infected patients were included (3584 from Pazhou and 2976 from Yongning). Of these, 90.6% received inactivated vaccines, 3.66% received recombinant SARS-CoV-2 spike protein subunit vaccines and 0.91% received adenovirus vaccines. Among the 6173 vaccinated individuals, 71.9% received a booster dose. By day 9, the isolation rate reached 50% among vaccinated patients. On day 7.5, the positive rate among vaccinated individuals reached 50%.

Conclusions: Full vaccination was effective, with heterologous vaccines showing greater efficacy than inactivated vaccines alone. However, there was no significant difference in the vaccine protective effect 12 months after vaccination.

Citing Articles

Reduced SARS-CoV-2 Infection Rates in Lab Workers Conducting Nucleic Acid Testing: Controlling for the Healthy Worker Effect.

Lin L, Chen Y, Lin G, Shen X, Yang T, Liu L J Epidemiol Glob Health. 2025; 15(1):10.

PMID: 39878891 PMC: 11780050. DOI: 10.1007/s44197-025-00343-8.

References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Zhang Y, Lv Q, Qi F, Li F, Deng R, Liang X . Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. Animal Model Exp Med. 2023; 6(1):51-56. PMC: 9986223. DOI: 10.1002/ame2.12302. View

3.
Krause P, Fleming T, Longini I, Peto R, Briand S, Heymann D . SARS-CoV-2 Variants and Vaccines. N Engl J Med. 2021; 385(2):179-186. PMC: 8262623. DOI: 10.1056/NEJMsr2105280. View

4.
Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

5.
Hoffmann M, Arora P, Gross R, Seidel A, Hornich B, Hahn A . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 184(9):2384-2393.e12. PMC: 7980144. DOI: 10.1016/j.cell.2021.03.036. View